Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Morphine
Drug ID BADD_D01498
Description Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805.[A176035] It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse.[A176050] Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941.[L12114]
Indications and Usage Morphine is used for the management of chronic, moderate to severe pain.[A176050] Opiods, including morphine, are effective for the short term management of pain. Patients taking opioids long term may need to be monitored for the development of physical dependence, addiction disorder, and drug abuse.[L5728]
Marketing Status approved; investigational
ATC Code N02AA01
DrugBank ID DB00295
KEGG ID D08233
MeSH ID D009020
PubChem ID 5288826
TTD Drug ID D0WE3O
NDC Product Code 42799-217
UNII 76I7G6D29C
Synonyms Morphine | Morphia | Morphine Chloride | Chloride, Morphine | Morphine Sulfate | Sulfate, Morphine | SDZ 202-250 | SDZ 202 250 | SDZ 202250 | SDZ202-250 | SDZ202 250 | SDZ202250 | Morphine Sulfate (2:1), Pentahydrate | MS Contin | Contin, MS | Oramorph SR | Duramorph | Morphine Sulfate (2:1), Anhydrous
Chemical Information
Molecular Formula C17H19NO3
CAS Registry Number 57-27-2
SMILES CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Intestinal ischaemia24.04.08.001; 07.15.02.0010.000223%Not Available
Intestinal obstruction07.13.01.0020.001114%Not Available
Intestinal perforation07.04.06.0020.000334%Not Available
Intracranial pressure increased17.07.02.002--Not Available
Intussusception07.13.01.0080.000111%Not Available
Ischaemic hepatitis24.04.07.004; 09.01.07.0180.000223%Not Available
Judgement impaired19.05.01.009; 17.03.03.005--Not Available
Large intestine perforation12.02.03.005; 07.04.06.0050.000724%
Laryngospasm22.04.02.002--
Learning disability19.21.05.0020.000167%Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.003420%
Leukocytosis01.02.01.002--
Leukoencephalopathy17.13.02.0030.001504%
Leukopenia01.02.02.001--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Livedo reticularis23.06.05.001; 24.03.04.0030.000278%Not Available
Liver disorder09.01.08.001--Not Available
Liver function test abnormal13.03.04.030--Not Available
Loss of consciousness17.02.04.0040.004233%Not Available
Lung disorder22.02.07.001--Not Available
Lung infiltration22.01.02.0040.000167%Not Available
Lymphadenopathy01.09.01.002--Not Available
Malaise08.01.01.003--
Mallory-Weiss syndrome24.07.02.038; 07.12.01.0040.000167%Not Available
Megacolon07.02.05.0020.000111%Not Available
Memory impairment19.20.01.003; 17.03.02.003--
Menstruation irregular21.01.01.005; 05.05.01.008--
Mental disability26.01.01.001--Not Available
Mental impairment17.03.03.002; 19.21.02.003--Not Available
Metabolic acidosis14.01.01.0030.001337%Not Available
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene